Cell and Gene Therapy Manufacturing Services Market by Type (Allogeneic, Autologous, Viral Vector, and Non-Viral Vector); Indication (Cancer, and Orthopedic); Application (Clinical, Commercial, and Others); End Use (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Other End Users), and Geography: Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00027026 | Pages: 100 | Industry: Biotechnology | Date: Oct 2022 | Type: Global

The market crossed the US$ 8.0 billion mark in 2022 and is expected to hit US$ 14.5 billion by 2030, recording a CAGR of 12.5% during the forecast period.

The Cell and gene therapy manufacturing services market has been significantly growing with the increase in the research and development activities in cell and gene therapies.

Other factors driving the growth of the market include rising number of agreements and partnerships between pharmaceutical key players, technological advancements, and growing interest in cancer research. In addition, increasing investments of pharmaceutical companies in developing novel drugs are fueling market growth. In 2021, the allogeneic segment held the maximum share due to increasing awareness about allogeneic cell therapy, growing funding for new cell lines, increasing partnerships and acquisitions, and the development of advanced genomics methods for cell analysis.   

Within the report, the market is segmented into  type, indication, application, end user, and geography.  Based on type, the market is segmented into allogeneic, autologous, viral vector, non-viral vector. On the basis of indications, the market is bifurcated into cancer and orthopedics. On the basis of applications, the market is segmented into clinical, commercial, and others. On the basis of end user, the medical device contract manufacturing market is into pharmaceutical and biotechnology companies, academic and research institutes, and other end users. Geographically, the market is sub segmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Get more information on this report :

Surge in number of cell and gene therapy clinical trials will provide future opportunity

Cell therapy is an emerging field in life science that utilizes normal cells for the restoration of damaged tissue. Cell therapies have shown immense potential in the management of several chronic disorders, such as cancer, immune deficiency, and other metabolic diseases. Gene therapy is a novel procedure that manipulates the genes to re-establish the loss of function to treat the underlying cause of the disease. With the increase in the prevalence of chronic diseases and the encouraging response of cell and gene therapies in its management, there has been significant interest in this field.

Recently, the investment in cell and gene therapy clinical trials has tremendously increased owing to a surge in demand for novel medicines to fulfill unmet medical needs. As per the data from PhRMA report on the cell & gene therapy pipeline in 2018, there were 289 cell & gene therapies in clinical development by biopharmaceutical companies. This number raised by 25% in 2020, with 362 cell & gene therapies in clinical development. In addition, according to data suggested by CGT Catapult, there were 154 ATMP clinical trials in the UK in 2020 in comparison to the 127 trials reported in 2019, suggesting an increase of more than 20%. This huge growth in the number of cell and gene therapy clinical trials is expected to drive the demand for manufacturing services and, in turn, propel growth in the cell & gene therapy manufacturing services market.

Increasing pharmaceutical investment is one of the major factors accelerating market growth.

Several pharmaceutical giants are actively investing in the development of new drugs. These companies invest in the research and development sector to deliver high-quality and innovative products for the management of diseases. The robust response of cell and gene therapies in managing chronic disorders has triggered several strategic alliances in this area, also driving the market's growth.

Recent strategic developments in the Cell and gene therapy manufacturing services market

The Cell and gene therapy manufacturing services market has undergone several significant developments, and a few of these have been mentioned below:

  • In 2021, Charles River Laboratories announced the acquisition of a cell & gene therapy CDMO; Cognate BioServices to enhance its cell and gene therapy manufacturing abilities.
  • In 2021, Thermo Fisher Scientific announced the acquisition Henogen S.A., for about USD 859.7 million. This acquisition will enhance its penetration in the cell and gene therapy manufacturing services market.
  • In 2019, Thermo Fisher Scientific announced the acquisition of Brammer Bio, a company engaged in viral vector manufacturing for gene and cell therapies, for approximately US$ 1.7 billion.

Several players drive the Cell and gene therapy manufacturing servicesmarket by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. Thermo Fisher Scientific Inc., Merck KGaA, Charles River Laboratories, Lonza, Catalent Inc., Takara Bio Inc., and F. Hoffmann-La Roche Ltd are among the prominent players operating in the market.

Target audience for the report:

  • Drug developing companies
  • Contract development and manufacturing organization,
  • Drug discovery-related associations, organizations, forums, and alliances
  • Government bodies, such as regulating authorities and policymakers
  • Venture capitalists, private equity firms, and start-up companies
  • Drug distributors and sales firms
  • End users of drug discovery
  • Research institutes, organizations, and consulting companies

Scope of the report:

In this report, the market has been segmented on the basis of:

  • Type:
    • Allogeneic
    • Autologous
    • Viral Vector
    • Non-Viral Vector
  • Indication:
    • Cancer
    • Orthopedic
  • Application:
    • Clinical
    • Commercial
    • Others
  • End User:
    • Pharmaceutical and Biotechnology Companies
    • Academic and Research Institutes
    • Others
  • Region
    • North America
    • Europe
    • Asia Pacific (APAC)
    • South & Central America
    • Middle East & Africa
  • Companies profiled
  • Thermo Fisher Scientific
  • Merck KGaA
  • Charles River Laboratories
  • Lonza
  • Catalent
  • WuXi AppTec
  • Takara Bio Inc.
  • Nikon Corporation
  • FUJIFILM Holdings Corporation
  • F. Hoffmann-La Roche Ltd.

The List of Companies
- Thermo Fisher Scientific
- Merck KGaA
- Charles River Laboratories
- Lonza
- Catalent
- WuXi AppTec
- Takara Bio Inc.
- Nikon Corporation
- FUJIFILM Holdings Corporation
- F. Hoffmann-La Roche Ltd.


Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$1500
Site License
$2500
Enterprise License
$3500